Transgenomic, Inc. (MASDAQ:TBIO) provides products for the purification and analysis of nucleic acids used in the life sciences industry for research primarily on molecular genetics and diagnostics. In June 2017, Transgenomic Stockholders and CT based Precipio Diagnostics Members approve the merger of the two firms. Post merger, the new firm cotinued to trade but now as Precipio, Inc. (PRPO). Transgenic had functioned as aglobal biotechnology company advancing personalized medicine in oncology and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR, which enables use of liquid biopsies for mutation detection, the company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies. Transgenomics diagnostic technologies are designed to improve medical diagnoses and patient outcomesThe company also provides genetic variation analytical services to the medical research, clinical, and pharmaceutical markets. Its principal product includes WAVE System, which has applicability to genetic variation detection in molecular genetic research and molecular diagnostics. The company also offers bio-consumable products; and consumable products that can be used on multiple independent platforms, which include SURVEYOR Nuclease and a range of high pressure liquid chromatography separation columns. In addition, it provides molecular clinical reference laboratory services, which specializes in mitochondrial and molecular diagnostic testing, including genetic testing for oncology, hematology, and inherited disorders, as well as pharmacogenomics research services. The company's customers include academic and medical institutions, as well as pharmaceutical, biotech, and commercial companies
